Published in Vaccine Weekly, October 26th, 2005
"Despite profound T cell immunodeficiency, most patients treated with chemotherapy do not succumb to infection. The basis for residual protective immunity in lymphopenic patients is not known. We prospectively measured T cell numbers, thymopoiesis, and T cell memory in 73 children undergoing a 2-year chemotherapy regimen for acute lymphoblastic leukemia (ALL) and compared them to an age-matched cohort of 805 healthy children," scientists writing in the journal Blood report.
"Most patients had profound defects in CD4 and CD8 T cell numbers at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly